The treatment blocked S-phase kinase-associated protein 2 and the Notch 1 intracellular domain (N1-ICD), suppressed the growth of ACC in vivo, reduced CD133+ cells and sensitized them to radiation, and led to the induction of cyclin-dependent kinase inhibitor 1B (p27Kip1). The gene discussed is CDKN1B; the disease is adrenal cortex carcinoma.